DePuy Orthopaedics Regulatory Problems with Hips, Knees Draw FDA Warning

Federal regulators are accusing Depuy Orthopaedics, a subsidiary of Johnson & Johnson, of selling artificial knee and hip replacement implants without approval. 

The FDA issued a warning letter to DePuy Orthopaedics last month about the regulatory problems, after inspectors visiting a plant in Warsaw, Indiana discovered a host of implants being manufactured there that were never given FDA approval.

The letter, released this week by the FDA, has forced DePuy to remove 14 different implant components from the market until the issue can be resolved.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

DePuy officials told FDA investigators that the components found at the plant were custom devices made for specific patients’ anatomies, and thus did not have to get premarket approval, even through the agency’s fast-track 501(k) approval process. However, the agency disagrees, saying that none of the devices qualify as custom devices.

“Although the devices’ size and shape may vary with each patient’s anatomy, the standardized design characteristics do not vary among the devices manufactured,” the FDA concluded. “The fact that final specifications are tailored to match a patient’s anatomy does not preclude a clinical study or submission of a marketing application for the devices.”

Not only should the devices not have been sold, but they were manufactured with poor quality control procedures, the FDA warning letter notes. The letter cites the company for using poor design validation procedures, not having a process in place for handling customer complaints and other regulatory violations.

DePuy Orthopaedics was the focus of a major artificial hip system recall in August 2010 when it pulled 93,000 ASR metal hip implants from the market. The ASR hip recall has triggered more than 3,500 lawsuits against the company.

At the time of the recall, Johnson & Johnson indicated that the DePuy ASR failure rate was about 12%. However, some expects have suggested that the actual percentage of people who are likely to experience problems with their implant, including loosening, metal poisoning and possible revision surgery, is going to be substantially higher as more time passes.

Since the recall, a growing flood of DePuy ASR hip implant lawsuits have been filed against Johnson & Johnson in state and federal courts throughout the United States. The federal DePuy ASR litigation has been consolidated for pretrial proceedings in the U.S. District Court for the Northern District of Ohio as part of an MDL, or multidistrict litigation.

1 Comments

  • JosephOctober 18, 2016 at 8:02 pm

    I had 3-total knee replacements in a 8- year span.. Because of faulty Depuy equipment..

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns
Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns (Posted today)

The FDA has issued a safety communication warning that Zimmer Biomet CPT hip system femoral stems may increase the risk of femur fractures, calling for doctors to avoid its use when possible.

Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference
Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference (Posted yesterday)

The judge presiding over all Change Healthcare lawsuits filed in federal court is holding the first status conference of the litigation, which is expected to grow significantly as Change Healthcare data breach letters continue to be sent to impacted customers.

Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury
Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury (Posted 2 days ago)

Complaint comes as a panel of federal judges are scheduled to hear oral arguments later this month, to determine whether all AngioDynamics port catheter lawsuits filed in U.S. District Courts nationwide should be centralized before one judge.